SEC Company Response from KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514) (KPRX) — Sep 30, 2014
KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514)
Date: Sept. 30, 2014 · CIK: 0001372514 · Accession: 0001144204-14-058774
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-197725
Letter
AEGIS CAPITAL CORP.
810 Seventh Avenue
11th Floor
New York, NY 10019
September 30, 2014
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Eyegate Pharmaceuticals, Inc.
Registration Statement, as amended on Form S-1 (File No. 333-197725)
Ladies and Gentlemen:
In accordance with the above-referenced Registration Statement, and pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), we, the representative of the several underwriters (the “Representative”), hereby join in the request of Eyegate Pharmaceuticals, Inc. that the effective time of the above-referenced Registration Statement be accelerated so that it will be declared effective at 5:00 p.m., Eastern time, on Thursday, October 2, 2014, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that during the period from September 15, 2014 to the date of this letter, the preliminary prospectus, dated September 12, 2014 and the preliminary prospectus dated September 26, 2014, in connection with the Registration Statement was distributed approximately as follows:
Copies to underwriters:
Copies to prospective dealers:
Copies to prospective institutional investors:
200 + E-Reds
Copies to prospective retail investors and others:
300 + E-Reds
Total:
1255 + E-Reds
The Representative confirms on behalf of itself and the several underwriters that they have complied and will continue to comply with the requirements of Rule 15c2-8 promulgated under of the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Very truly yours,
AEGIS CAPITAL CORP.
Show Raw Text
CORRESP
1
filename1.htm
AEGIS CAPITAL CORP.
810 Seventh Avenue
11th Floor
New York, NY 10019
September 30, 2014
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re:
Eyegate Pharmaceuticals, Inc.
Registration Statement, as amended on Form
S-1 (File No. 333-197725)
Ladies and Gentlemen:
In accordance with the above-referenced
Registration Statement, and pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission
under the Securities Act of 1933, as amended (the “Securities Act”), we, the representative of the several underwriters
(the “Representative”), hereby join in the request of Eyegate Pharmaceuticals, Inc. that the effective time of the
above-referenced Registration Statement be accelerated so that it will be declared effective at 5:00 p.m., Eastern time, on Thursday,
October 2, 2014, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities
Act, please be advised that during the period from September 15, 2014 to the date of this letter, the preliminary prospectus, dated
September 12, 2014 and the preliminary prospectus dated September 26, 2014, in connection with the Registration Statement was distributed
approximately as follows:
Copies to underwriters:
430
Copies to prospective dealers:
325
Copies to prospective institutional investors:
200 + E-Reds
Copies to prospective retail investors and others:
300 + E-Reds
Total:
1255 + E-Reds
The Representative confirms on behalf of
itself and the several underwriters that they have complied and will continue to comply with the requirements of Rule 15c2-8 promulgated
under of the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Very truly yours,
AEGIS CAPITAL CORP.
As Representative of the several
Underwriters
By:
/s/ Samuel Guidetti______
Name: Samuel Guidetti
Title: Chief Compliance Officer
[Signature Page to Representative Acceleration
Request]